Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
St. John's Regional Health Center
mi
from
Springfield, MO
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Billings Clinic - Downtown
mi
from
Billings, MT
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Billings Clinic - Downtown
mi
from
Billings, MT
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Great Falls Clinic - Main Facility
mi
from
Great Falls, MT
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Great Falls Clinic - Main Facility
mi
from
Great Falls, MT
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Good Samaritan Hospital
mi
from
Dayton, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
CCOP - Dayton
mi
from
Dayton, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Columbia Basin Hematology
mi
from
Kennewick, WA
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Columbia Basin Hematology
mi
from
Kennewick, WA
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Kapiolani Medical Center at Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Oncare Hawaii, Incorporated - Pali Momi
mi
from
'Aiea, HI
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Oncare Hawaii, Incorporated - Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Air Force Base, OH
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Georgetown University
mi
from
Washington,
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Johns Hopkins
mi
from
Baltimore, MD
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Michigan
mi
from
Ann Arbor, MI
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Duke University
mi
from
Durham, NC
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Baylor University
mi
from
Houston, TX
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Baylor University
mi
from
Houston, TX
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
NorthShore University HealthSystem
mi
from
Evanston, IL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
San Juan Oncology
mi
from
Farmington, NM
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
San Juan Oncology
mi
from
Farmington, NM
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Use of Dermal Matrix in Breast Reconstruction
The Use of An Acellular Dermal Matrix Sling in a Two-stage Breast REconstruciton After Mastectomy: A Double-blinded Randomized Trial
Status: Enrolling
Updated:  3/13/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Use of Dermal Matrix in Breast Reconstruction
The Use of An Acellular Dermal Matrix Sling in a Two-stage Breast REconstruciton After Mastectomy: A Double-blinded Randomized Trial
Status: Enrolling
Updated: 3/13/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer
Status: Enrolling
Updated:  3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer
Status: Enrolling
Updated: 3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Primary Breast Cancer Occurring Concomitant With Pregnancy
Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy
Status: Enrolling
Updated:  3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Primary Breast Cancer Occurring Concomitant With Pregnancy
Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy
Status: Enrolling
Updated: 3/14/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer
Status: Enrolling
Updated:  3/14/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer
Status: Enrolling
Updated: 3/14/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated:  3/15/2018
Northwestern University
mi
from
Chicago, IL
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated: 3/15/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated:  3/15/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Status: Enrolling
Updated: 3/15/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Click here to add this to my saved trials
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer
Status: Enrolling
Updated:  3/16/2018
Georgetown University Hospital
mi
from
Washington,
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer
Status: Enrolling
Updated: 3/16/2018
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Calcitriol, Physical Activity, and Bone Health in Cancer Survivors
A Pilot Study of the Effects of High-Dose Oral Calcitriol and Physical Activity on Bone Health in Breast Cancer Survivors
Status: Enrolling
Updated:  3/16/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Calcitriol, Physical Activity, and Bone Health in Cancer Survivors
A Pilot Study of the Effects of High-Dose Oral Calcitriol and Physical Activity on Bone Health in Breast Cancer Survivors
Status: Enrolling
Updated: 3/16/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions
Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions.
Status: Enrolling
Updated:  3/19/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions
Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions.
Status: Enrolling
Updated: 3/19/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials